Recursion Pharmaceuticals Stock Is Sliding Wednesday: What's Going On?
Portfolio Pulse from Adam Eckert
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares fell after reporting mixed Q4 results, missing revenue estimates but beating EPS expectations. The company is progressing with clinical programs and integrating AI through a partnership with Tempus. Needham maintained a Buy rating, raising the target price. Nvidia's investment in Recursion was highlighted.
February 28, 2024 | 2:32 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Recursion Pharmaceuticals reported mixed Q4 results, with revenue below estimates but a smaller-than-expected EPS loss. The company is advancing clinical programs and integrating AI, supported by a partnership with Tempus. Needham raised the target price from $15 to $17.
The stock's short-term negative reaction is likely due to the revenue miss, despite the EPS beat and positive developments in clinical programs and AI integration. The analyst upgrade indicates underlying strength, but the immediate market reaction has been negative.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100